Rick Gonzalez, AbbVie CEO (Pablo Martinez Monsivais/AP Images)
January 17, 2024 12:35 PM EST
Pharma

Hu­mi­ra biosim­i­lar mar­ket re­mains stag­nant, with Ab­b­Vie los­ing on­ly 2% of mar­ket share, Sam­sung re­port shows

Zachary Brennan

Senior Editor

Ab­b­Vie is show­ing off to the world how it’s main­tain­ing most of the sales vol­ume for the Hu­mi­ra (adal­i­mum­ab) fran­chise in the US, los­ing just …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times